Characterization of Patients in the International Severe Asthma Registry with High Steroid Exposure Who Did or Did Not Initiate Biologic Therapy

Wenjia Chen 1, Mohsen Sadatsafavi 2, Trung N Tran 3, Ruth B Murray 4, Chong Boon Nigel Wong 1, Nasloon Ali 4 5, Cono Ariti 4 5, Esther Garcia Gil 6, Anthony Newell 5 7, Marianna Alacqua 8, Mona Al-Ahmad 9, Alan Altraja 10, Riyad Al-Lehebi 11 12, Mohit Bhutani 13, Leif Bjermer 14, Anne Sofie Bjerrum 15, Arnaud Bourdin 16, Lakmini Bulathsinhala 4 5, Anna von Bülow 17, John Busby 18, Giorgio Walter Canonica 19 20, Victoria Carter 4 5, George C Christoff 21, Borja G Cosio 22, Richard W Costello 23, J Mark FitzGerald 24, João A Fonseca 25, Kwang Ha Yoo 26, Liam G Heaney 27, Enrico Heffler 19 20, Mark Hew 28 29, Ole Hilberg 30, Flavia Hoyte 31 32, Takashi Iwanaga 33, David J Jackson 34 35, Rupert C Jones 36, Mariko Siyue Koh 37 38, Piotr Kuna 39, Désirée Larenas-Linnemann 40, Sverre Lehmann 41, Lauri A Lehtimäki 42 43, Juntao Lyu 5 7, Bassam Mahboub 44 45, Jorge Maspero 46 47, Andrew N Menzies-Gow 48, Concetta Sirena 49, Nikolaos Papadopoulos 50 51, Andriana I Papaioannou 52, Luis Pérez de Llano 53 54, Diahn-Warng Perng 55 56, Matthew Peters 57, Paul E Pfeffer 58 59, Celeste M Porsbjerg 17, Todor A Popov 60, Chin Kook Rhee 61, Sundeep Salvi 62, Camille Taillé 63, Christian Taube 64, Carlos A Torres-Duque 65, Charlotte S Ulrik 66, Seung Won Ra 67, Eileen Wang 31 32, Michael E Wechsler 68, David B Price 4 5 69

Affiliations

21 October 2022

-

doi: 10.2147/JAA.S377174

Abstract

Background: Many severe asthma patients with high oral corticosteroid exposure (HOCS) often do not initiate biologics despite being eligible. This study aimed to compare the characteristics of severe asthma patients with HOCS who did and did not initiate biologics.

Methods: Baseline characteristics of patients with HOCS (long-term maintenance OCS therapy for at least 1 year, or ≥4 courses of steroid bursts in a year) from the International Severe Asthma Registry (ISAR; https://isaregistries.org/), who initiated or did not initiate biologics (anti-lgE, anti-IL5/5R or anti-IL4R), were described at the time of biologic initiation or registry enrolment. Statistical relationships were tested using Pearson's chi-squared tests for categorical variables, and t-tests for continuous variables, adjusting for potential errors in multiple comparisons.

Results: Between January 2015 and February 2021, we identified 1412 adult patients with severe asthma from 19 countries that met our inclusion criteria of HOCS, of whom 996 (70.5%) initiated a biologic and 416 (29.5%) did not. The frequency of biologic initiation varied across geographical regions. Those who initiated a biologic were more likely to have higher blood eosinophil count (483 vs 399 cells/µL, p=0.003), serious infections (49.0% vs 13.3%, p<0.001), nasal polyps (35.2% vs 23.6%, p<0.001), airflow limitation (56.8% vs 51.8%, p=0.013), and uncontrolled asthma (80.8% vs 73.2%, p=0.004) despite greater conventional treatment adherence than those who did not start a biologic. Both groups had similar annual asthma exacerbation rates in the previous 12 months (5.7 vs 5.3, p=0.147).

Conclusion: Around one third of severe HOCS asthma patients did not receive biologics despite a similar high burden of asthma exacerbations as those who initiated a biologic therapy. Other disease characteristics such as eosinophilic phenotype, serious infectious events, nasal polyps, airflow limitation and lack of asthma control appear to dictate biologic use.

Keywords: biologics; patient characteristics; real-world; severe asthma; treatment pattern.

Conflict of interest statement

Mohsen Sadatsafavi has received honoraria from AZ, BI, and GSK for purposes unrelated to the content of this manuscript and has received research funding from AZ and BI directly into his research account from AZ for unrelated projects. Trung N. Tran is an employee of AstraZeneca. AstraZeneca is a co-funder of the International Severe Asthma Registry. Nigel Chong Boon Wong reports grants from Optimum Patient Care Global, grants from AstraZeneca Ltd, during the conduct of the study. Nasloon Ali was an employee of Observational and Pragmatic Research Institute (OPRI) at the time this research was conducted. OPRI conducted this study in collaboration with Optimum Patient Care and AstraZeneca. Con Ariti is an employee of the Observational and Pragmatic Research Institute (OPRI). OPRI conducted this study in collaboration with Optimum Patient Care and AstraZeneca. Esther Garcia Gil was an employee of AstraZeneca at the time this research was conducted. AstraZeneca is a co-funder of the International Severe Asthma Registry. Anthony Newell was an employee of Optimum Patient Care (OPC) at the time this research was conducted. OPC is a co-funder of the International Severe Asthma Registry. Marianna Alacqua was an employee of AstraZeneca at the time this research was conducted. AstraZeneca is a co-funder of the International Severe Asthma Registry. Mona Al-Ahmad has received advisory board and speaker fees from AstraZeneca, Sanofi, Novartis, and GlaxoSmithKline. Alan Altraja has received lecture fees from AstraZeneca, Berlin-Chemie Menarini, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MSD, Norameda, Novartis, Orion, Sanofi, and Zentiva; personal fees from Teva, Shire Pharmaceuticals and CSL Behring, sponsorships from AstraZeneca, Berlin-Chemie Menarini, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, MSD, Norameda, Sanofi, and Novartis; and has been a member of advisory boards for AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Sanofi, and Teva. Riyad Al-Lehebi has given lectures at meetings supported by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, and Sanofi, reports personal fees from Novartis and participated in advisory board fees from GlaxoSmithKline. Mohit Bhutani: has received advisory board and speaker fees from AstraZeneca, GlaxoSmithKline, Pfizer, Sanofi Genzyme, Covis pharmaceuticals; has been an investigator on clinical trials sponsored by AstraZeneca, GlaxoSmithKline, Sanofi Genzyme, Boehringer Ingelheim Leif Bjermer has (in the last three years) received lecture or advisory board fees from Alk-Abello, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Sanofi, Genzyme/Regeneron, and Teva. Anne-Sofie Bjerrum has received lecture fees from Astra Zeneca, GlaxoSmithKline, Novartis. Arnaud Bourdin has received industry-sponsored grants from AstraZeneca-MedImmune, Boehringer-Ingelheim, Cephalon/Teva, GlaxoSmithKline, Novartis, Sanofi-Regeneron and consultancies with AstraZeneca-MedImmune, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, Regeneron-Sanofi, Med-in-Cell, Actelion, Merck, Roche, and Chiesi. Lakmini Bulathsinhala is an employee of the Observational and Pragmatic Research Institute (OPRI). OPRI conducted this study in collaboration with Optimum Patient Care and AstraZeneca. Anna von Bülow reports speakers fees and consultancy fees from AstraZeneca, GSK and Novartis, outside the submitted work. She has also attended advisory board for Novartis and AstraZeneca. John Busby reports personal fees from NuvoAir, outside the submitted work. Giorgio Walter Canonica has received research grants, as well as lecture or advisory board fees from A. Menarini, Alk-Albello, Allergy Therapeutics, Anallergo, AstraZeneca, MedImmune, Boehringer Ingelheim, Chiesi Farmaceutici, Circassia, Danone, Faes, Genentech, Guidotti Malesci, GlaxoSmithKline, Hal Allergy, Merck, MSD, Mundipharma, Novartis, Orion, Sanofi Aventis, Sanofi, Genzyme/Regeneron, Stallergenes, UCB Pharma, Uriach Pharma, Teva, Thermo Fisher, and Valeas. Victoria Carter is an employee of Optimum Patient Care, a co-funder of the International Severe Asthma Registry and reports grants from Optimum Patient Care Global, during the conduct of the study Borja G. Cosio declares grants from Chiesi, AstraZeneca, Menarini, Teva and GSK; personal fees for advisory board activities from Chiesi, GSK, Novartis, Sanofi, Menarini, Teva and AstraZeneca; and payment for lectures/speaking engagements from Chiesi, Novartis, GSK, Menarini, Sanofi, Teva and AstraZeneca, outside the submitted work. Richard W. Costello has received honoraria for lectures from Aerogen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, and Teva. He is a member of advisory boards for GlaxoSmithKline and Novartis, has received grant support from GlaxoSmithKline and Aerogen, has received personal fees from Respirasense, personal fees from PfizerBioNTech, during the conduct of the study and has patents in the use of acoustics in the diagnosis of lung disease, assessment of adherence and prediction of exacerbations, issued to 212. J. Mark FitzGerald reports grants from AstraZeneca, GSK, Sanofi Regeneron, Novartis paid directly to UBC. Personal fees for lectures and attending advisory boards: AstraZeneca, GSK, Sanofi Regeneron, TEVA. João A Fonseca reports grants from or research agreements with AstraZeneca, Mundipharma, Sanofi Regeneron and Novartis. Personal fees for lectures and attending advisory boards: AstraZeneca, GSK, Mundipharma, Novartis, Sanofi Regeneron and TEVA. Liam G. Heaney declares he has received grant funding, participated in advisory boards and given lectures at meetings supported by Amgen, AstraZeneca, Boehringer Ingelheim, Circassia, Evelo Biosciences, Hoffmann la Roche, GlaxoSmithKline, Novartis, Theravance and Teva; he has taken part in asthma clinical trials sponsored by Boehringer Ingelheim, Hoffmann la Roche, and GlaxoSmithKline for which his institution received remuneration; he is the Academic Lead for the Medical Research Council Stratified Medicine UK Consortium in Severe Asthma which involves industrial partnerships with a number of pharmaceutical companies including Amgen, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Hoffmann la Roche, and Janssen. Enrico Heffler participates in speaking activities and industry advisory committees for AstraZeneca, Sanofi-Genzyme, GSK, Novartis, Regeneron, Stallergenes-Greer, TEVA, Circassia and Nestlè Purina, grants from AstraZeneca and GSK Mark Hew declares grants and other advisory board fees (made to his institutional employer) from AstraZeneca, GlaxoSmithKline, Novartis, Sanofi, and Seqirus, for unrelated projects. Flavia Hoyte declares honoraria from AstraZeneca. She has been an investigator on clinical trials sponsored by GlaxoSmithKline, Genentech, Teva, Sanofi and National Institute of Allergy and Infectious Diseases (NIAID), for which her institution has received funding. Takashi Iwanaga declares grants from Astellas, Boehringer Ingelheim, Daiichi-Sankyo, Kyorin, MeijiSeika Pharma, Teijin Pharma, Ono, and Taiho, and lecture fees from Kyorin, GlaxoSmithKline, Sanofi and AstraZeneca. David J. Jackson has received advisory board and speaker fees from AstraZeneca, GlaxoSmithKline, Boehringer Ingelheim, Teva, Napp, Chiesi, Sanofi Regeneron, Novartis and research grant funding from AstraZeneca. Rupert C. Jones declares grants from Astra Zeneca, Glaxo Smith Kline, Novartis OPRI and Teva and personal fees for consultancy, speakers’ fees or travel support from Astra Zeneca, Boehringer Ingelheim, Glaxo Smith Kline, Novartis and OPRI. Mariko Siyue Koh reports grant support from AstraZeneca, and honoraria for lectures and advisory board meetings paid to her hospital (Singapore General Hospital) from GlaxoSmithKline, AstraZeneca, Sanofi and Boehringer Ingelheim, outside the submitted work. Piotr Kuna reports personal fees from Adamed, personal fees from AstraZeneca, personal fees from Berlin Chemie Manarini, personal fees from Boehringer Ingelheim, personal fees from Lekam, personal fees from Novartis, personal fees from Chiesi, personal fees from Polpharma, personal fees from Sanofi, personal fees from Teva, personal fees from Zentiva, personal fees from FAES, personal fees from Glenmark, outside the submitted work Désirée Larenas Linnemann reports speaker or personal fees from ALK, Alakos, Armstrong, AstraZeneca, Boehringer Ingelheim, Chiesi, DBV Technologies, Gossamer, Grunenthal, GSK, Mylan/Viatris, Menarini, MSD, Novartis, Pfizer, Purina institute, Sanofi, Siegfried, UCB, Carnot, Viatris, and grants from Sanofi, AbbVie, ALK, AstraZeneca, Circassia, Chiesi, GSK, Lilly, Novartis, Pfizer, Purina Institute and UCB, outside the submitted work Sverre Lehmann declares receipt of lecture (personal) and advisory board (to employer) fees from AstraZeneca, Boehringer Ingelheim, and Novartis. Lauri A. Lehtimäki declares personal fees for consultancy, lectures and attending advisory boards from ALK, AstraZeneca, Boehringer Ingelheim, Circassia, Chiesi, GlaxoSmithKline, Mundipharma, Novartis, Orion Pharma, Sanofi, and Teva. Juntao Lyu is an employee of Optimum Patient Care (OPC). OPC is a co-funder of the International Severe Asthma Registry. Jorge Maspero reports grants and personal fees from AstraZeneca, Sanofi, Novartis, and GSK, personal fees from IMMUNOTEK, personal fees from SANOFI, outside the submitted work. Andrew N. Menzies-Gow has attended advisory boards for AstraZeneca, GlaxoSmithKline, Novartis, Regeneron, Sanofi and Teva, andhas received speaker fees from AstraZeneca, Novartis, Teva and Sanofi. He has participated in research with AstraZeneca for which his institution has been remunerated and has attended international conferences with Teva. He has had consultancy agreements with AstraZeneca and Sanofi. Nikolaos G. Papadopoulos declares research support from Gerolymatos, Menarini, Nutricia, and Vian; and consultancy/speaker fees from ASIT, AZ, Boehringer Ingelheim, GSK, HAL Allergy, Medscape, Menarini, MSD, Mylan, Novartis, and Nutricia, OM Pharma, Sanofi, and Takeda, grant from Capricare. Andriana I. Papaioannou has received fees and honoraria from Menarini, GSK, Novartis, Elpen, Boehringer Ingelheim, AstraZeneca, and Chiesi. Luis Perez-de-Llano declares non-financial support, personal fees, and grants from Teva, Sanofi and AstraZeneca, Chesi; non-financial support and personal fees from Boehringer Ingelheim, Esteve, GlaxoSmithKline, Mundipharma, and Novartis; personal fees from MSD, TECHDOW PHARMA, Leo-Pharma, GEBRO and GILEAD; non-financial support from Menairi, grants, non-financial support from FAES during the conduct of the study. Diahn-Warng Perng (Steve) received sponsorship to attend or speak at international meetings, honoraria for lecturing or attending advisory boards, and research grants from the following companies: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Daiichi Sankyo, Shionogi and Orient Pharma Matthew Peters declares personal fees and non-financial support from AstraZeneca and GlaxoSmithKline. Paul E. Pfeffer has attended advisory boards for AstraZeneca, Sanofi and GSK; has given lectures at meetings supported by AstraZeneca and GlaxoSmithKline; has taken part in clinical trials sponsored by AstraZeneca, GlaxoSmithKline, Sanofi and Novartis, for which his institution received remuneration; non-financial support from Chiesi; and has a current research grant funded by GlaxoSmithKline. Celeste M. Porsbjerg has attended advisory boards for AstraZeneca, Novartis, TEVA, and Sanofi-Genzyme; has given lectures at meetings supported by AstraZeneca, Novartis, TEVA, Sanofi-Genzyme, and GlaxoSmithKline; has taken part in clinical trials sponsored by AstraZeneca, Novartis, MSD, Sanofi-Genzyme, GlaxoSmithKline, and Novartis; and has received educational and research grants from AstraZeneca, Novartis, TEVA, GlaxoSmithKline, ALK, and Sanofi-Genzyme. Todor A. Popov declares relevant research support from Novartis and Chiesi Pharma. Chin Kook Rhee declares consultancy and lecture fees from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Mundipharma, MSD, Novartis, Sandoz, Sanofi, Takeda, and Teva-Handok. Sundeep Salvi declares research support and speaker fees from Cipla, Glenmark, GSK Camille Taillé has received lecture or advisory board fees and grants to her institution from AstraZeneca, Sanofi, GlaxoSmithKline, Chiesi and Novartis, for unrelated projects. Carlos A. Torres-Duque has received fees as advisory board participant and/or speaker from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Novartis, and Sanofi-Aventis; has taken part in clinical trials from AstraZeneca, Novartis and Sanofi-Aventis; has received unrestricted grants for investigator-initiated studies at Fundacion Neumologica Colombiana from AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Grifols and Novartis. Charlotte S. Ulrik has attended advisory boards for AstraZeneca, ALK-Abello, GSK, Boehringer-Ingelheim, Novartis, Chiesi, TEVA, and Sanofi-Genzyme; has given lectures at meetings supported by AstraZeneca, Sandoz, Mundipharma, Chiesi, Boehringer-Ingelheim, Orion Pharma, Novartis, TEVA, Sanofi-Genzyme, and GlaxoSmithKline; has taken part in clinical trials sponsored by AstraZeneca, Novartis, Merck, InsMed, ALK-Abello, Sanofi-Genzyme, GlaxoSmithKline, Boehringer-Ingelheim, Regeneron, Chiesi and Novartis; and has received educational and research grants from AstraZeneca, MundiPharma, Boehringer-Ingelheim, Novartis, TEVA, GlaxoSmithKline and Sanofi-Genzyme; has received personal fees from Pfizer. Seung Won Ra has received lecture fees from AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Novartis. Eileen Wang has received honoraria from AstraZeneca, GlaxoSmithKline, Wefight, and Clinical Care Options. She has been an investigator on clinical trials sponsored by AstraZeneca, GlaxoSmithKline, Genentech, Novartis, Teva, and Sanofi, for which her institution has received funding. She has received personal fees from Wefight. Michael E. Wechsler reports receiving consulting honoraria from AstraZeneca, Boehringer Ingelheim, Genentech, GSK, Novartis, Regeneron, Sanofi and Teva; personal fees from Amgen, Avalo, Cerecor, Cytoreason, Eli Lilly, Equillium, Incyte, Kinaset, Phylaxis, Pulmatrix, Rapt and Sound Biologics. David B. Price has advisory board membership with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals, Thermofisher; consultancy agreements with Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from AstraZeneca, Boehringer Ingelheim, Chiesi, Circassia, Mylan, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service; payment for lectures/speaking engagements from AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Mundipharma, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel/accommodation/meeting expenses from AstraZeneca, Boehringer Ingelheim, Mundipharma, Mylan, Novartis, Thermofisher; funding for patient enrolment or completion of research from Novartis; stock/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); 5% shareholding in Timestamp which develops adherence monitoring technology; is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment; and was an expert witness for GlaxoSmithKline. The authors report no other conflicts of interest in this work.

Figures

Figure 1 Flowchart of cohort creation.

Figure 1 Flowchart of cohort creation.

Figure 2 Geographic distribution of adult severe asthma patients with high oral corticosteroid exposure enrolled in ISAR according to biologic initiation status. ISAR: International Severe Asthma Registry. Data are presented as % not initiated/% initiated. Green: approximately equal proportion of biologic non-initiators to initiators; Blue: More likely not to initiate biologics; Yellow: more likely to initiate biologics.

Figure 2 Geographic distribution of adult severe asthma patients with high oral corticosteroid exposure enrolled in ISAR according to biologic initiation status. ISAR: International Severe Asthma Registry. Data are presented as % not initiated/% initiated. Green: approximately equal proportion of biologic non-initiators to initiators; Blue: More likely not to initiate biologics; Yellow: more likely to initiate biologics.

Figure 3 Clinical characteristics of adult severe asthma patients with high oral corticosteroid exposure enrolled in ISAR who did and did not initiate biologic therapy.

Figure 3 Clinical characteristics of adult severe asthma patients with high oral corticosteroid exposure enrolled in ISAR who did and did not initiate biologic therapy.

Similar articles

Comparative effectiveness of Anti-IL5 and Anti-IgE biologic classes in patients with severe asthma eligible for both.

Pfeffer PE, Ali N, Murray R, Ulrik C, Tran TN, Maspero J, Peters M, Christoff GC, Sadatsafavi M, Torres-Duque CA, Altraja A, Lehtimäki L, Papadopoulos NG, Salvi S, Costello RW, Cushen B, Heffler E, Iwanaga T, Al-Ahmad M, Larenas-Linnemann D, Kuna P, Fonseca JA, Al-Lehebi R, Rhee CK, Perez-de-Llano L, Perng Steve DW, Mahboub B, Wang E, Goh C, Lyu J, Newell A, Alacqua M, Belevskiy AS, Bhutani M, Bjermer L, Bjornsdottir U, Bourdin A, Bulow AV, Busby J, Canonica GW, Cosio BG, Dorscheid DR, Muñoz-Esquerre M, FitzGerald JM, Gil EG, Gibson PG, Heaney LG, Hew M, Hilberg O, Hoyte F, Jackson DJ, Koh MS, Ko HB, Lee JH, Lehmann S, Chaves Loureiro C, Lúðvíksdóttir D, Menzies-Gow AN, Mitchell P, Papaioannou AI, Popov TA, Porsbjerg CM, Salameh L, Sirena C, Taillé C, Taube C, Tohda Y, Wechsler ME, Price DB.Allergy. 2023 Mar 17. doi: 10.1111/all.15711. Online ahead of print.PMID: 36929509

Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study.

Menzies-Gow AN, McBrien C, Unni B, Porsbjerg CM, Al-Ahmad M, Ambrose CS, Dahl Assing K, von Bülow A, Busby J, Cosio BG, FitzGerald JM, Garcia Gil E, Hansen S, aHeaney LG, Hew M, Jackson DJ, Kallieri M, Loukides S, Lugogo NL, Papaioannou AI, Larenas-Linnemann D, Moore WC, Perez-de-Llano LA, Rasmussen LM, Schmid JM, Siddiqui S, Alacqua M, Tran TN, Suppli Ulrik C, Upham JW, Wang E, Bulathsinhala L, Carter VA, Chaudhry I, Eleangovan N, Murray RB, Price CA, Price DB.J Asthma Allergy. 2022 Jan 13;15:63-78. doi: 10.2147/JAA.S328653. eCollection 2022.PMID: 35046670 Free PMC article.

Asthma biologics: Real-world effectiveness, impact of switching biologics, and predictors of response.

Abbas F, Georas S, Cai X, Khurana S.Ann Allergy Asthma Immunol. 2021 Dec;127(6):655-660.e1. doi: 10.1016/j.anai.2021.08.416. Epub 2021 Sep 3.PMID: 34481992

Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.

Katsaounou P, Buhl R, Brusselle G, Pfister P, Martínez R, Wahn U, Bousquet J.Respir Med. 2019 Apr;150:51-62. doi: 10.1016/j.rmed.2019.02.003. Epub 2019 Feb 7.PMID: 30961951 Review.

Biologics for oral corticosteroid-dependent asthma.

Yılmaz İ.Allergy Asthma Proc. 2020 May 1;41(3):151-157. doi: 10.2500/aap.2020.41.200015.PMID: 32375958 Review.

Cited by

Can we predict who will benefit most from biologics in severe asthma? A post-hoc analysis of two phase 3 trials.

Chen W, Reddel HK, FitzGerald JM, Beasley R, Janson C, Sadatsafavi M.Respir Res. 2023 May 2;24(1):120. doi: 10.1186/s12931-023-02409-2.PMID: 37131185 Free PMC article. Clinical Trial.

KMEL References

https://pubmed.ncbi.nlm.nih.gov/

References

  1.  
    1. Reddel HK, Taylor DR, Bateman ED., et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180:59–99. doi:10.1164/rccm.200801-060ST - DOI - PubMed
  2.  
    1. Luskin AT, Antonova EN, Broder MS, et al. Health care resource use and costs associated with possible side effects of high oral corticosteroid use in asthma: a claims-based analysis. Clinicoecon Outcomes Res. 2016;8:641–648. doi:10.2147/CEOR.S115025 - DOI - PMC - PubMed
  3.  
    1. Canonica GW, Colombo GL, Bruno GM, et al. Shadow cost of oral corticosteroids-related adverse events: a pharmacoeconomic evaluation applied to real-life data from the Severe Asthma Network in Italy (SANI) registry. World Allergy Org J. 2019;12:100007. doi:10.1016/j.waojou.2018.12.001 - DOI - PMC - PubMed
  4.  
    1. Price DB, Trudo F, Voorham J, et al. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;11:193–204. doi:10.2147/JAA.S176026 - DOI - PMC - PubMed
  5.  
    1. Sweeney J, Patterson CC, Menzies-Gow A, et al. Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax. 2016;71:339–346. doi:10.1136/thoraxjnl-2015-207630 - DOI - PubMed
  6.  
    1. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 years. Rheumatology. 2011;50:1982–1990. doi:10.1093/rheumatology/ker017 - DOI - PubMed
  7.  
    1. Tran TN, King E, Sarkar R, et al. Oral Corticosteroid Prescription Patterns for Asthma in France, Germany, Italy, and the United Kingdom. Eur Respir J. 2020. doi:10.1183/13993003.02363-2019 - DOI - PMC - PubMed
  8.  
    1. Tran TN, MacLachlan S, Hicks W, et al. Oral Corticosteroid Treatment Patterns of Patients in the United States with Persistent Asthma. J Allergy Clin Immunol Pract. 2021;9:338–346.e3. doi:10.1016/j.jaip.2020.06.019 - DOI - PubMed
  9.  
    1. Bleecker ER, Menzies-Gow AN, Price DB, et al. Systematic Literature Review of Systemic Corticosteroid Use for Asthma Management. Am J Respir Crit Care Med. 2020;201:276–293. doi:10.1164/rccm.201904-0903SO - DOI - PMC - PubMed
  10.  
    1. Voorham J, Xu X, Price DB, et al. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma. Allergy. 2019;74:273–283. doi:10.1111/all.13556 - DOI - PMC - PubMed
  11.  
    1. Wang E, Wechsler ME, Tran TN, et al. Characterization of Severe Asthma Worldwide: data From the International Severe Asthma Registry. Chest. 2020;157:790–804. doi:10.1016/j.chest.2019.10.053 - DOI - PubMed
  12.  
    1. Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma. Allergy. 2020;75:1023–1042. doi:10.1111/all.14221 - DOI - PubMed
  13.  
    1. Krings JG, McGregor MC, Bacharier LB, et al. Biologics for Severe Asthma: treatment-Specific Effects Are Important in Choosing a Specific Agent. J Allergy Clin Immunol. 2019;7:1379–1392. doi:10.1016/j.jaip.2019.03.008 - DOI - PubMed
  14.  
    1. Porsbjerg CM, Menzies-Gow AN, Tran TN, et al. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma. J Allergy Clin Immunol Pract. 2022;10:1202–1216. doi:10.1016/j.jaip.2021.12.027 - DOI - PubMed
  15.  
    1. Brown T, Jones T, Gove K, et al. Randomised controlled trials in severe asthma: selection by phenotype or stereotype. Eur Respir J. 2018:52. doi:10.1183/13993003.01444-2018 - DOI - PubMed
  16.  
    1. FitzGerald JM, Tran TN, Alacqua M, et al. International Severe Asthma Registry (ISAR): protocol for a global registry. BMC Med Res Methodol. 2020;20(1):212. - PMC - PubMed
  17.  
    1. Bulathsinhala L, Eleangovan N, Heaney LG, et al. Development of the International Severe Asthma Registry (ISAR): a Modified Delphi Study. J Allergy Clin Immunol Pract. 2019;7:578–588.e2. doi:10.1016/j.jaip.2018.08.016 - DOI - PubMed
  18.  
    1. ISAR Study Group. International Severe Asthma Registry (ISAR): mission Statement. Chest. 2020;157:805–814. - PubMed
  19.  
    1. Wang E, Wechsler ME, Tran TN, et al. Characterization of severe asthma worldwide: data from the International Severe Asthma Registry (ISAR). Chest. 2020;157:805–814. - PubMed
  20.  
    1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease; 2018. Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-rev.... Accessed September 28, 2022.
  21.  
    1. Heaney LG. Eosinophilic and Noneosinophilic Asthma: an Expert Consensus Framework to Characterize Phenotypes in a Global Real-Life Severe Asthma Cohort. CHEST. 2021. doi:10.1016/j.chest.2021.04.013 - DOI - PubMed
  22.  
    1. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Statistical Soc Series B. 1995;57:289–300.
  23.  
    1. Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma (GINA) Strategy 2021 - Executive summary and rationale for key changes. Eur Respir J. 2021. doi:10.1183/13993003.02730-2021 - DOI - PMC - PubMed
  24.  
    1. Inselman JW, Jeffery MM, Maddux JT, et al. Trends and Disparities in Asthma Biologic Use in the United States. J Allergy Clin Immunol Pract. 2020;8:549–554.e1. doi:10.1016/j.jaip.2019.08.024 - DOI - PMC - PubMed
  25.  
    1. Bel EH, Wenzel SE, Thompson PJ, et al. Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma. N Eng J Med. 2014;371:1189–1197. doi:10.1056/NEJMoa1403291 - DOI - PubMed
  26.  
    1. Nair P, Wenzel S, Rabe KF, et al. Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma. N Eng J Med. 2017;376:2448–2458. doi:10.1056/NEJMoa1703501 - DOI - PubMed
  27.  
    1. Rabe KF, Nair P, Brusselle G, et al. Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. N Eng J Med. 2018;378:2475–2485. doi:10.1056/NEJMoa1804093 - DOI - PubMed
  28.  
    1. FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet. 2016;388:2128–2141. doi:10.1016/S0140-6736(16) - DOI - PubMed
  29.  
    1. Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3:355–366. doi:10.1016/S2213-2600(15) - DOI - PubMed
  30.  
    1. Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380:651–659. doi:10.1016/S0140-6736(12) - DOI - PubMed
  31.  
    1. Jackson DJ, Busby J, Pfeffer PE, et al. Characterisation of patients with severe asthma in the UK Severe Asthma Registry in the biologic era. Thorax. 2021;76:220–227. doi:10.1136/thoraxjnl-2020-215168 - DOI - PMC - PubMed
  32.  
    1. Ortega H, Gleich G, Mayer B, et al. Reproducibility of a Single Blood Eosinophil Measurement as a Biomarker in Severe Eosinophilic Asthma. Annals ATS. 2015;12:1896–1897. doi:10.1513/AnnalsATS.201507-443LE - DOI - PubMed
  33.  
    1. Tinoco EM, Gigante AR, Fernandes AL, et al. Impact of biologic therapy in severe asthma with nasal polyps. Eur Respir J. 2021:58. doi:10.1183/13993003.congress-2021.PA3739 - DOI
  34.  
    1. Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394:1638–1650. doi:10.1016/S0140-6736(19) - DOI - PubMed
  35.  
    1. Rogliani P, Calzetta L, Matera MG, et al. Severe Asthma and Biological Therapy: when, Which, and for Whom. Pulm Ther. 2020;6:47–66. doi:10.1007/s41030-019-00109-1 - DOI - PMC - PubMed
  36.  
    1. Matera MG, Calzetta L, Sanduzzi A, et al. Effects of neuraminidase on equine isolated bronchi. Pulm Pharmacol Ther. 2008;21:624–629. doi:10.1016/j.pupt.2008.02.003 - DOI - PubMed
  37.  
    1. d’Ancona G, Kavanagh J, Roxas C, et al. Adherence to Inhaled Corticosteroids and Clinical Outcomes in Mepolizumab Therapy for Severe Asthma. Eur Respir J. 2020. doi:10.1183/13993003.02259-2019 - DOI - PubMed
  38.  
    1. Alahmadi FH, Simpson AJ, Gomez C, et al. Medication Adherence in Patients With Severe Asthma Prescribed Oral Corticosteroids in the U-BIOPRED Cohort. Chest. 2021;160:53–64. doi:10.1016/j.chest.2021.02.023 - DOI - PubMed
  39.  
    1. Tiotiu A. Applying personalized medicine to adult severe asthma. Allergy Asthma Proc. 2021;42:e8–16. doi:10.2500/aap.2021.42.200100 - DOI - PubMed
  40.  
    1. Taillé C, Devillier P, Dusser D, et al. Evaluating response to biologics in severe asthma: precision or guesstimation? Respir Med Res. 2021;80:100813. doi:10.1016/j.resmer.2021.100813 - DOI - PubMed
  41.  
    1. Bossios A. Inflammatory T2 Biomarkers in Severe Asthma Patients: the First Step to Precision Medicine. J Allergy Clin Immunol Pract. 2021;9:2689–2690. doi:10.1016/j.jaip.2021.04.044 - DOI - PubMed

Page Navigation